In late June, Russia's Pharmstandard was reportedly considering a sale of its OTC business. A couple of weeks later, the company said it would spin the unit off instead. But the fate of that business is still up in the air, with a sale to another drugmaker still a possibility, Chairman Viktor Kharitonin tells Bloomberg.
Canadian devicemaker EMcision International has sold the first units of its pancreatic tumor ablation catheter, the Habib RF Duo 13, in Europe and China, notching a foothold to gain further insight into the device's efficacy.
CRO Icon has signed a deal with the National Taiwan University Hospital, lending its weight in clinical research to help make local trials faster and more reliable.
Sanofi has joined GlaxoSmithKline under China's official corruption microscope. According to the state news service Xinhua, authorities are investigating allegations that the French drugmaker bribed more than 500 doctors.
Taiwanese contract manufacturer ScinoPharm and Chinese CRO Sundia MediTech are pooling their resources to cash in on the demand for outsourced services in China.
According to The Economic Times, India's patent appeals board revoked the patents covering glaucoma treatments Ganfort and Combigan, both used to reduce pressure inside the eye. The action came following a patent challenge from domestic drugmaker Ajanta Pharma.
Sanofi has joined GlaxoSmithKline in facing bribery allegations in China. According to a Chinese newspaper, the whistleblower says Sanofi paid 1.7 million yuan in bribes to 503 doctors around the country.
India's Ranbaxy Laboratories has been manufacturing drugs in Malaysia since before anyone was talking about emerging markets. Now, it is about ready to expand on that position with a second plant in the country.
GE Healthcare has bought Brazil's Omnimed, a producer of patient monitoring devices, part of the conglomerate's effort to increase its share of the Latin American market.
In another swipe at the intellectual property of drugmakers in emerging markets, China's State Intellectual Property Office (SIPO) has yanked the patent for Viread, saying it lacks novelty.